Enjaymo Disease Interactions
There are 4 disease interactions with Enjaymo (sutimlimab).
Sutimlimab (applies to Enjaymo) autoimmune disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder
Sutimlimab may increase the risk for developing autoimmune diseases such as systemic lupus erythematosus (SLE). Patients with SLE or autoimmune disease with positive antinuclear antibody were excluded from clinical trials with sutimlimab. In clinical trials, some patients developed a relapse or worsening of autoimmune disease. Patients receiving sutimlimab should be monitored for signs/symptoms and managed medically.
Sutimlimab (applies to Enjaymo) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The effects of liver dysfunction on the pharmacokinetics of sutimlimab are unknown.
Sutimlimab (applies to Enjaymo) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Sutimlimab may increase susceptibility to serious infections, including those caused by encapsulated bacteria. If this drug is administered to patients with active systemic infections, close monitoring for signs/symptoms of worsening infection is recommended. Interruption of treatment should be considered in patients who are undergoing treatment for serious infection. Patients should be vaccinated and/or revaccinated against encapsulated bacteria according to clinical recommendations, ideally at least 2 weeks before starting treatment. Sutimlimab has not been studied in chronic infections such a hepatitis B, hepatitis C, or HIV.
Sutimlimab (applies to Enjaymo) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The effects of severe renal dysfunction on the pharmacokinetics of sutimlimab are unknown.
Switch to professional interaction data
Enjaymo drug interactions
There are 77 drug interactions with Enjaymo (sutimlimab).
Report options
More about Enjaymo (sutimlimab)
- Enjaymo consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Afinitor Disperz
Afinitor Disperz is used for subependymal giant cell astrocytoma, tuberous sclerosis complex
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Arava
Arava (leflunomide) is used to treat the symptoms of rheumatoid arthritis and help reduce joint ...
Arzerra
Arzerra is used to treat chronic lymphocytic leukemia (CLL), usually in combination with other ...
Aubagio
Aubagio (teriflunomide) is used to reduce flare-ups in people with relapsing multiple sclerosis ...
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
